StockData
AstraZeneca PLC logo

AstraZeneca PLC

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca Core R&D expense by Quarter

Core R&D expense ($M) ($M)

QuarterlyAnnual

AstraZeneca Core R&D expense: -$3,662M in Q2 2026, up 6.1% from a year earlier.

Latest, Q2 2026
-3,662
Period ended Jun 30, 2026
Change on a year earlier
+6.1%
-3,453 in Q2 2025
History
23 quarters
Since Q4 2020
Sources
23
Documents cited below

Where the Q2 2026 figure comes from

“|| R&D expense | | (4,053) | | | 36 | | | 355 | | – | | (3,662) | 6 | 5”

Source: Form 6-K FY2026Q2 Earnings Release ↗

Reported in Form 6-K Quarterly & Form 20-F Reported-to-Core Reconciliation.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCore R&D expense ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026-3,662+6.1%Form 6-K FY2026Q2 Earnings Release ↗
Q1 2026Mar 31, 2026-3,461+12.1%Form 6-K FY2026Q1 Earnings Release ↗
Q4 2025Dec 31, 2025-3,731+4.4%Form 6-K FY2025Q4 Earnings Release ↗
Q3 2025Sep 30, 2025-3,550+15.7%Form 6-K FY2025Q3 Earnings Release ↗
Q2 2025Jun 30, 2025-3,453+20.2%Form 6-K FY2025Q2 Earnings Release ↗
Q1 2025Mar 31, 2025-3,088+14.5%Form 6-K FY2025Q1 Earnings Release ↗
Q4 2024Dec 31, 2024-3,573+22.6%Form 6-K FY2024Q4 Earnings Release ↗
Q3 2024Sep 30, 2024-3,068+23.5%Form 6-K FY2024Q3 Earnings Release ↗
Q2 2024Jun 30, 2024-2,872+11.8%Form 6-K FY2024Q2 Earnings Release ↗
Q1 2024Mar 31, 2024-2,698+17.3%Form 6-K FY2024Q1 Earnings Release ↗
Q4 2023Dec 31, 2023-2,914+15.4%Form 6-K FY2023Q4 Earnings Release ↗
Q3 2023Sep 30, 2023-2,485+5.4%Form 6-K FY2023Q3 Earnings Release ↗
Q2 2023Jun 30, 2023-2,568+5.6%Form 6-K FY2023Q2 Earnings Release ↗
Q1 2023Mar 31, 2023-2,300+5.2%Form 6-K FY2023Q1 Earnings Release ↗
Q4 2022Dec 31, 2022-2,526+5.4%Form 6-K FY2022Q4 Earnings Release ↗
Q3 2022Sep 30, 2022-2,357+9.5%Form 6-K FY2022Q3 Earnings Release ↗

Breakdown

What makes up core R&D expense

Cite this data

StockData. (2026). AstraZeneca Core R&D expense ($M), quarterly Q4 2020–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/core-rd

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.